Organisation paid for research Program year 2025 Source: CMS Open Payments

Tyler Rsrch Inst LLC

Neither a doctor nor a teaching hospital

Research payments

$6,526,782

1,672 payments

Through program year 2025, Tyler Rsrch Inst LLC is reported as receiving $6,526,782 in research payments, across 1,672 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$838,934	384
2024	Research	$2,304,897	878
2023	Research	$2,299,592	318
2022	Research	$199,807	23
2021	Research	$355,025	18
2020	Research	$305,646	16
2019	Research	$222,880	35

Breakdown

Who paid Research payments · program years 2019–2025

Janssen Research & Development, LLC $6,526,782 1,672 payments

Studies the money was for Research payments · program years 2019–2025

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease $2,766,769 283 payments
78934804Crd2001 $2,225,995 749 payments
78934804Uco2001 $639,658 285 payments
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) $585,393 210 payments
Cnto1959crd3004 $141,728 81 payments
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) $83,069 31 payments
Cnto1959crd3007 $38,982 8 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease $15,900 3 payments
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis $15,336 13 payments
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) $8,657 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.